Share & more
South African generic drug manufacturer Thembalami Pharmaceuticals is out of the running in the government's anti-AIDS drug tender.
Thembalami, a joint venture between the leading local drug firm, Adcock Ingram, and India's Ranbaxy, was until recently one of three generic drug producers on a short list of nine that included drug giants GlaxoSmithKline and Boehringer Ingelheim.
Ranbaxy's withdrawal of four antiretroviral drugs from the South African market last week meant Thembalami automatically fell out of the tendering process.
The planned rollout of antiretroviral drugs in South Africa is the biggest in the world, making its drug tender a lucrative prize for the chosen drug manufacturer.
This article was produced by IRIN News while it was part of the United Nations Office for the Coordination of Humanitarian Affairs. Please send queries on copyright or liability to the UN. For more information: https://shop.un.org/rights-permissions